Substantial Equivalence
In accordance with the requirements of 21 CFR 807.93, this summary is formatted with the Agency’s final rule, “...510(k) Summaries and 510(k) Statements...” and can be used to provide equivalence summary to anyone requesting it from the Agency.

Manufacturer: Opus Medical, 27127 Calle Arroyo, Suite 1924 San Juan Capistrano, CA. 92675

Contact Person: Laura Kasperowicz, Ph: (949) 234-0400, Fax: 234-0493 E-Mail: Lkasperowicz@opusmedical.com

Date Prepared: October 19, 2004

Device Information

Trade Name: Opus Magnum™ Anchor with Inserter
Common Name: Bone Anchor, Fastener, Fixation, Soft Tissue
Classification Name: Fastener, Fixation, Non-degradable, Soft Tissue
Classification: Class II per 21 CFR 888.3040; Product Code: HTY

Substantial Equivalence
The Opus Magnum™ Anchor with Inserter is substantially equivalent to the existing Opus Magnum™ Anchor with Inserter cleared by the Food and Drug Administration.

Indications For Use
The Opus Magnum™ bone anchor with inserter is indicated for use in fixation of soft tissue to bone for rotator cuff repair.

Executive Summary and Reason for 510(k) Notification
The purpose of this 510(k) is to notify the FDA of a proposed modification to the Magnum™ Bone Anchor. The modified Opus Magnum™ is substantially equivalent to the Opus Magnum™ Anchor originally cleared under 510(k) 012125. The intended use, indications for use, and technology of the modified Magnum Anchor are the same as the original Magnum Anchor.
Ms. Laura Kasperowicz  
Regulatory Affairs  
Opus Medical, Inc.  
27127 Calle Arroyo, Suite 1924  
San Juan Capistrano, California 92675

Re: K042914  
Trade/Device Name: Opus Magnum™ Bone Anchor with Inserter  
Regulation Number: 21 CFR 888.3040  
Regulation Name: Smooth or threaded metallic bone fixation fastener  
Regulatory Class: II  
Product Code: MBI, HTY  
Dated: October 19, 2004  
Received: October 21, 2004

Dear Ms. Kasperowicz:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA’s issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act’s requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at (240) 276-0120. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address http://www.fda.gov/cdrh/dsma/dsmamain.html

Sincerely yours,

Celia M. Witten, Ph.D., M.D.
Director
Division of General, Restorative and Neurological Devices
Office of Device Evaluation
Center for Devices and Radiological Health

Enclosure
SECTION 3: STATEMENT OF INDICATIONS FOR USE

510(k) Number (if known): 04 2914

Device Name: Opus Magnum™ Bone Anchor with Inserter

Indications for Use:

The Opus Magnum™ bone anchor with inserter is indicated for use in fixation of soft tissue to bone for rotator cuff repair.

Prescription Use X OR Over-The-Counter Use
(Per CFR 801.109)

(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)

(Division Sign-Off)
Division of General, Restorative, and Neurological Devices

510(k) Number 04 2914